Importantly, we also propose that combination therapy with the dual PI3K/mTOR inhibitor dactolisib can sensitise lung adenocarcinomas to platinum chemotherapy, although only in the context TP53 WT or TP53 null tumours. This evidence concerns the gene MTOR and lung adenocarcinoma.